Literature DB >> 19551767

Melatonin as a potential therapeutic agent in psychiatric illness.

Maria D Maldonado1, Russel J Reiter, Maria A Pérez-San-Gregorio.   

Abstract

The aim of this review was to summarize the potential use of melatonin in the treatment of mental disorders, specifically bipolar disorders, depression, and schizophrenia. To date, melatonin has been most commonly used in psychiatry because of its hypnotic, rhythm resynchronizing, and antioxidant actions. Here, we examine other properties of the melatonin including its anti-inflammatory, antinociceptive, anxiolytic, and drug detoxification actions as well as its protective effects against neural loss. The brain is an intricate sensory and motor organ which receives information from both the external and internal environments. It transduces information into complex chemical and electrical signals which are transmitted throughout the central nervous system (CNS) and the organism. The pathogenesis of mental disorders remains ambiguous and neuroinflammation has been proposed as a causative agent. We consider the potential contributions of melatonin as therapeutic agent in CNS and during neuroinflammation in mental disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19551767     DOI: 10.1002/hup.1032

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  18 in total

1.  Secretion of melatonin and 6-sulfatoxymelatonin urinary excretion in functional dyspepsia.

Authors:  Cezary Chojnacki; Tomasz Poplawski; Grażyna Klupinska; Janusz Blasiak; Jan Chojnacki; Russel J Reiter
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

2.  Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.

Authors:  Lone Baandrup; Birgitte Fagerlund; Birte Glenthoj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-11       Impact factor: 5.270

3.  Depression and Altitude: Cross-Sectional Community-Based Study Among Elderly High-Altitude Residents in the Himalayan Regions.

Authors:  Motonao Ishikawa; Gaku Yamanaka; Naomune Yamamoto; Takashi Nakaoka; Kiyohito Okumiya; Kozo Matsubayashi; Kuniaki Otsuka; Hiroshi Sakura
Journal:  Cult Med Psychiatry       Date:  2016-03

Review 4.  Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.

Authors:  George Anderson; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-04-25       Impact factor: 3.584

Review 5.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

6.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

7.  Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol.

Authors:  Lone Baandrup; Birgitte Fagerlund; Poul Jennum; Henrik Lublin; Jane L Hansen; Per Winkel; Christian Gluud; Bob Oranje; Birte Y Glenthoj
Journal:  BMC Psychiatry       Date:  2011-10-05       Impact factor: 3.630

Review 8.  Role of melatonin in schizophrenia.

Authors:  Armando L Morera-Fumero; Pedro Abreu-Gonzalez
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

Review 9.  The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders.

Authors:  Sonia Mediouni; Maria Cecilia Garibaldi Marcondes; Courtney Miller; Jay P McLaughlin; Susana T Valente
Journal:  Front Microbiol       Date:  2015-10-23       Impact factor: 5.640

Review 10.  The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia.

Authors:  Elisa Ridolfi; Cinzia Barone; Elio Scarpini; Daniela Galimberti
Journal:  Clin Dev Immunol       Date:  2013-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.